Facebook Twitter LinkedIn Google Plus RSS

J&J completes $650M acquisition of Aragon Pharmaceuticals

By

New Brunswick-based Johnson & Johnson announced it has successfully completed its acquisition of Aragon Pharmaceuticals Inc. The deal closed for $650 million in cash upfront, with the potential for an additional $350 million in future milestone payments, spokesman Al Wasilewski said today.

Those numbers mirror what was first reported on the acquisition in June.

Development of compounds from Aragon's androgen receptor antagonist program, including its lead androgen receptor signaling inhibitor, ARN-509, will be managed by Janssen Research & Development LLC.

Digital content editor Joe Ross is @joeross on Twitter.

Write to the Editorial Department at editorial@njbiz.com

Related Stories

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close
Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!